Greg O’Brien is a reporter from Brewster, Mass. He is the former editor and publisher of the Cape Codder and an award-winning writer. O’Brien was diagnosed with early-onset Alzheimer's disease in 2010. The following is an excerpt from a speech he gave on March 13, 2014.
Lisa Genova is the author of Still Alice, a fictional book about a professor dealing with early-onset Alzheimer's disease. Here, she discusses the book and its upcoming film adaptation starring Julianne Moore, Kristen Stewart and Alec Baldwin.
Bruce Yankner, M.D., Ph.D., led a recent study (not funded by Cure Alzheimer's Fund) on a protein called REST. His results suggest that this protein may protect neurons from damage such as oxidative stress and inflammation. The study also gives us clues as to why plaques and tangles, two well-known features of Alzheimer's pathology, may not always cause cognitive decline.
Reporter Greg O'Brien is determined to document his struggle with early-onset Alzheimer's. This film is directed by Steve James and was created as part of David Shenk's "Living With Alzheimer's" series.
Despite the progress being made on the Alzheimer’s disease front, awareness continues to be a huge issue—not only of the disease itself, but of what causes it and how it progresses.
The Willoughby Golf Club in Stuart, Fla., raised awareness and understanding of Alzheimer's with its Second Annual Wellness Day. CAF Research Consortium Chairman Rudy Tanzi, Ph.D., spoke about the disease at a luncheon, which was followed by a lively Q&A. It was a full house with 120 attendees and the questions continued long after the event was over.
Our congratulations to Dr. Thomas C. Sϋdhof of Stanford University, a member of Cure Alzheimer’s Fund's Research Consortium, who joins Randy Scheckman of the University of California, Berkeley and James E. Rothman of Yale University in winning the Nobel Prize in Physiology or Medicine as announced today.
Consensus among Alzheimer’s researchers about the origins of the disease is growing. Most, including members of Cure Alzheimer’s Fund Research Consortium, agree that a combination of factors, beginning with the excessive build-up of the peptide Abeta42 triggering the development of tau tangles, nerve cell death, and inflammation are all required for Alzheimer’s pathology.
A new study by David Holtzman of Cure Alzheimer’s Fund’s Research Consortium published by the journal “Science Translational Medicine” brings sharp new focus on the direct relationship between the accumulation of Abeta in the brain and notorious sleep problems associated with Alzheimer's disease. This NIH-funded study (also supported by Ellison Medical Foundation) was made possible by early pilot studies initiated by the Cure Alzheimer's Fund --- another great example of leveraging innovative research ideas into substantially funded, high impact projects.